Barclays downgraded Exelixis to Equal Weight from Overweight with an unchanged price target of $25. The analyst cites a lack of near-to-mid term catalysts for the downgrade, saying investors are are unlikely to see high impact data in 2024. Consequently, the firm sees greater upside potential from other stocks in its coverage universe. In addition, a positive intellectual property outcome for Exelixis is mostly baked into consensus estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL: